These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23323145)

  • 1. The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
    El-Amm J; Aragon-Ching JB
    Ther Adv Med Oncol; 2013 Jan; 5(1):25-40. PubMed ID: 23323145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A changing landscape in castration-resistant prostate cancer treatment.
    Felici A; Pino MS; Carlini P
    Front Endocrinol (Lausanne); 2012; 3():85. PubMed ID: 22826702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metastatic castration-resistant prostate cancer.
    Antonarakis ES
    Eur Urol Rev; 2011; 6(2):90-96. PubMed ID: 23789039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel options for the treatment of castration-resistant prostate cancer.
    Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
    World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic castration-resistant prostate cancer: time for innovation.
    Tucci M; Scagliotti GV; Vignani F
    Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
    Bitting RL; Armstrong AJ; George DJ
    Clin Med Insights Oncol; 2011; 5():325-32. PubMed ID: 22084621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G; Sternberg CN
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
    Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
    Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
    Zafeiriou Z; Jayaram A; Sharp A; de Bono JS
    Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging novel therapies for advanced prostate cancer.
    Osanto S; Van Poppel H
    Ther Adv Urol; 2012 Feb; 4(1):3-12. PubMed ID: 22295041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDV3100 for the treatment of prostate cancer.
    Mukherji D; Pezaro CJ; De-Bono JS
    Expert Opin Investig Drugs; 2012 Feb; 21(2):227-33. PubMed ID: 22229405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of metastatic castration-resistant prostate cancer: recent advances.
    Mukherji D; Eichholz A; De Bono JS
    Drugs; 2012 May; 72(8):1011-28. PubMed ID: 22621691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.
    Gartrell BA; Saad F
    Ther Adv Urol; 2015 Aug; 7(4):194-202. PubMed ID: 26445599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C; Mourey L; Pouessel D; Ploussard G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.